Ryan Limbocker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5281966/publications.pdf

Version: 2024-02-01

687335 610883 1,082 29 13 24 citations h-index g-index papers 33 33 33 1377 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic. Natural Product Reports, 2022, 39, 742-753.	10.3	27
2	Utilization of Standardized College Entrance Metrics to Predict Undergraduate Student Success in Chemistry. Journal of Chemical Education, 2022, 99, 1725-1733.	2.3	1
3	A Brain-Permeable Aminosterol Regulates Cell Membranes to Mitigate the Toxicity of Diverse Pore-Forming Agents. ACS Chemical Neuroscience, 2022, 13, 1219-1231.	3.5	7
4	Investigation of Molecular Countermeasures to Modulate the Populations and Toxicity of A \hat{l}^2 42 Oligomers. Biophysical Journal, 2021, 120, 202a.	0.5	0
5	Therapeutics Against Protein Misfolded Oligomers in Neurodegenerative Diseases. Biophysical Journal, 2021, 120, 286a.	0.5	O
6	Cell Membrane Properties can Mediate the Toxicity of Protein Misfolded Oligomers and Folded Toxins. Biophysical Journal, 2021, 120, 308a.	0.5	0
7	Comparative Studies in the A30P and A53T α-Synuclein C. elegans Strains to Investigate the Molecular Origins of Parkinson's Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 552549.	3.7	12
8	Squalamine and Its Derivatives Modulate the Aggregation of Amyloid- \hat{l}^2 and \hat{l}_\pm -Synuclein and Suppress the Toxicity of Their Oligomers. Frontiers in Neuroscience, 2021, 15, 680026.	2.8	34
9	Two human metabolites rescue a C. elegans model of Alzheimer's disease via a cytosolic unfolded protein response. Communications Biology, 2021, 4, 843.	4.4	6
10	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8651.	4.1	23
11	Non-Pharmaceutical Interventions and Military Hygiene at the United States Military Academy between 1890 and 1910. Military Medicine, 2020, 185, e2104-e2109.	0.8	1
12	A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease. Scientific Reports, 2020, 10, 15280.	3.3	15
13	Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism. Communications Biology, 2020, 3, 435.	4.4	44
14	Impact of COVID-19 on General Chemistry Education at the United States Military Academy. Journal of Chemical Education, 2020, 97, 2922-2927.	2.3	11
15	Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's disease. Science Advances, 2020, 6, .	10.3	95
16	Rational design of a conformation-specific antibody for the quantification of $A\hat{l}^2$ oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13509-13518.	7.1	61
17	Rationally Designed Antibodies as Research Tools to Study the Structure–Toxicity Relationship of Amyloid-l² Oligomers. International Journal of Molecular Sciences, 2020, 21, 4542.	4.1	12
18	Trodusquemine enhances ${\sf A}^2$ 42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nature Communications, 2019, 10, 225.	12.8	111

#	Article	lF	CITATIONS
19	Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of Amyloid-Beta42 Aggregation in Alzheimer's Disease. Biophysical Journal, 2018, 114, 225a.	0.5	2
20	Massively parallel C. elegans tracking provides multi-dimensional fingerprints for phenotypic discovery. Journal of Neuroscience Methods, 2018, 306, 57-67.	2.5	52
21	Modulating Amyloid-Beta Aggregation to Reduce the Toxicity of its Oligomeric Aggregates. Biophysical Journal, 2018, 114, 430a.	0.5	2
22	Regional Differences in Dopamine Release in the R6/2 Mouse Caudate Putamen. Electroanalysis, 2018, 30, 1066-1072.	2.9	7
23	O2â€02â€02: TARGETING AMYLOID FORMATION USING RATIONALLY DESIGNED ANTIBODIES. Alzheimer's and Dementia, 2018, 14, P611.	0.8	0
24	Multistep Inhibition of \hat{l}_{\pm} -Synuclein Aggregation and Toxicity <i>iin Vitro</i> and <i>iin Vivo</i> by Trodusquemine. ACS Chemical Biology, 2018, 13, 2308-2319.	3.4	86
25	A natural product inhibits the initiation of $\hat{l}\pm$ -synuclein aggregation and suppresses its toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1009-E1017.	7.1	231
26	Attenuating the Toxicity of Amyloid-Beta Aggregation with Specific Species. Biophysical Journal, 2017, 112, 494a.	0.5	1
27	Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E200-E208.	7.1	180
28	Impaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with Carboplatin. ACS Chemical Neuroscience, 2016, 7, 689-699.	3.5	39
29	Localized Drug Application and Sub-Second Voltammetric Dopamine Release Measurements in a Brain Slice Perfusion Device. Analytical Chemistry, 2014, 86, 4151-4156.	6.5	18